Calypte Biomedical Corp. (CBMC) Financials Nov 14, 2014, 4:00 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Calypte Biomedical Corp.
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 725,000 1.01M 444,000 579,000 230,000
Cost of Goods Sold (COGS) incl. D&A 685,000 847,000 260,000 417,000 216,000
COGS excluding D&A 227,000 400,000 5,000 219,000 51,000
Depreciation & Amortization Expense 458,000 447,000 255,000 198,000 165,000
Depreciation 240,000 174,000 37,000 29,000 22,000
Amortization of Intangibles 218,000 273,000 218,000 169,000 143,000
Gross Income 40,000 165,000 184,000 162,000 14,000
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 7.27M 1.86M 1.28M 1.14M 969,000
Research & Development 1.41M 193,000 282,000 296,000 259,000
Other SG&A 5.86M 1.67M 999,000 839,000 710,000
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 (8.5M) 0 0
EBIT after Unusual Expense 0 0 8.5M 0 0
Non Operating Income/Expense 257,000 (318,000) 2.43M 103,000 1,000
Non-Operating Interest Income 1,000 1,000 0 - 0
Equity in Affiliates (Pretax) 0 0 0 0 -
Interest Expense 2.52M 1.59M 425,000 1,000 122,000
Gross Interest Expense 2.52M 1.59M 425,000 1,000 122,000
Interest Capitalized 0 0 0 0 0
Pretax Income (9.49M) (3.61M) 9.41M (871,000) (1.08M)
Income Tax 0 2,000 181,000 (178,000) 0
Income Tax - Current Domestic 0 - - (178,000) -
Income Tax - Current Foreign 0 - - 0 -
Income Tax - Deferred Domestic 0 - - 0 -
Income Tax - Deferred Foreign 0 - - 0 -
Income Tax Credits 0 - - 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) (3.05M) (1,000) 0 0 0
Consolidated Net Income (12.54M) (3.61M) 9.23M (693,000) (1.08M)
Minority Interest Expense (313,000) (320,000) 0 0 0
Net Income (12.22M) (3.29M) 9.23M (693,000) (1.08M)
Extraordinaries & Discontinued Operations 0 0 (267,000) 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - - 0 0 0
Discontinued Operations 0 0 (267,000) 0 0
Net Income After Extraordinaries (12.22M) (3.29M) 8.96M (693,000) (1.08M)
Preferred Dividends 0 0 120,000 0 0
Net Income Available to Common (12.22M) (3.29M) 9.11M (693,000) (1.08M)
EPS (Basic) (0.03) (0.01) 0.02 () ()
Basic Shares Outstanding 398.99M 450.24M 487.62M 545.85M 666.87M
EPS (Diluted) (0.03) (0.01) 0.02 () ()
Diluted Shares Outstanding 398.99M 450.24M 487.62M 545.85M 666.87M
EBITDA (6.77M) (1.25M) (842,000) (775,000) (790,000)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Calypte Biomedical Corp.
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 725,000 1.01M 444,000 579,000 230,000
Cost of Goods Sold (COGS) incl. D&A 685,000 847,000 260,000 417,000 216,000
COGS excluding D&A 227,000 400,000 5,000 219,000 51,000
Depreciation & Amortization Expense 458,000 447,000 255,000 198,000 165,000
Depreciation 240,000 174,000 37,000 29,000 22,000
Amortization of Intangibles 218,000 273,000 218,000 169,000 143,000
Gross Income 40,000 165,000 184,000 162,000 14,000
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 7.27M 1.86M 1.28M 1.14M 969,000
Research & Development 1.41M 193,000 282,000 296,000 259,000
Other SG&A 5.86M 1.67M 999,000 839,000 710,000
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 (8.5M) 0 0
EBIT after Unusual Expense 0 0 8.5M 0 0
Non Operating Income/Expense 257,000 (318,000) 2.43M 103,000 1,000
Non-Operating Interest Income 1,000 1,000 0 - 0
Equity in Affiliates (Pretax) 0 0 0 0 -
Interest Expense 2.52M 1.59M 425,000 1,000 122,000
Gross Interest Expense 2.52M 1.59M 425,000 1,000 122,000
Interest Capitalized 0 0 0 0 0
Pretax Income (9.49M) (3.61M) 9.41M (871,000) (1.08M)
Income Tax 0 2,000 181,000 (178,000) 0
Income Tax - Current Domestic 0 - - (178,000) -
Income Tax - Current Foreign 0 - - 0 -
Income Tax - Deferred Domestic 0 - - 0 -
Income Tax - Deferred Foreign 0 - - 0 -
Income Tax Credits 0 - - 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) (3.05M) (1,000) 0 0 0
Consolidated Net Income (12.54M) (3.61M) 9.23M (693,000) (1.08M)
Minority Interest Expense (313,000) (320,000) 0 0 0
Net Income (12.22M) (3.29M) 9.23M (693,000) (1.08M)
Extraordinaries & Discontinued Operations 0 0 (267,000) 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - - 0 0 0
Discontinued Operations 0 0 (267,000) 0 0
Net Income After Extraordinaries (12.22M) (3.29M) 8.96M (693,000) (1.08M)
Preferred Dividends 0 0 120,000 0 0
Net Income Available to Common (12.22M) (3.29M) 9.11M (693,000) (1.08M)
EPS (Basic) (0.03) (0.01) 0.02 () ()
Basic Shares Outstanding 398.99M 450.24M 487.62M 545.85M 666.87M
EPS (Diluted) (0.03) (0.01) 0.02 () ()
Diluted Shares Outstanding 398.99M 450.24M 487.62M 545.85M 666.87M
EBITDA (6.77M) (1.25M) (842,000) (775,000) (790,000)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
